Cargando…
Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies
During the last several years, multiple gene rearrangements with oncogenic potential have been described in NSCLC, identifying specific clinic-pathological subgroups of patients that benefit from a targeted therapeutic approach, including anaplastic lymphoma kinase (ALK), c-ros protooncogene 1 (ROS1...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7815353/ https://www.ncbi.nlm.nih.gov/pubmed/33489820 http://dx.doi.org/10.21037/tlcr-2019-cnsclc-06 |